Abstract: It is an object of the present invention to provide: a protein refolding column filler, which is effective for the refolding, namely, the activation of the function, of an inactive protein with an as yet unformed higher order structure produced in Escherichia coli or the like, or a protein whose conformation has been changed due to a certain cause and which has become inactivated; and a column filled with the aforementioned column filler. The present invention provides a protein refolding column filler, which comprises zeolite with BEA structure (Zeolite Beta) that is granulated into a particle state.

Abstract: It is an object of the present invention to provide a targeting agent, which enables the delivery of a drug to tumor sites or the imaging of tumor sites by utilizing its effect of accumulating to such tumor sites. The present invention provides a targeting agent for tumor site, which comprises a hydrophilic polymer-modified carrier coated with a gelatin-like protein that has repeats of a sequence represented by Gly-X—Y characteristic to collagen and has two or more sequences of cell adhesion signals in a single molecule wherein X and Y each independently represent an amino acid and a plurality of Gly-X—Y sequences may be the same or different.

Abstract: The present invention is to provide a medicinal composition for preventing or treating parasitic protozoan infections, having a high selective toxicity against parasitic protozoan infection, and a superior preventive or treating effect.

Abstract: An object of the present invention is to provide a microorganism which has a high ability of producing docosahexaenoic acid. The present invention provides a Thraustochytrium strain which has an ability of producing docosahexaenoic acid, and use thereof.

Abstract: There is provided a method of managing production quantity that includes determining a standard inventory quantity of products to be stocked in the single delivery center for a time of at least one predetermined cycle ahead based on a shipment record of the single delivery center, and determining a total assembly quantity of products to be assembled by the at least one factory for a time of at least one predetermined cycle ahead based on the determined standard inventory quantity of the single delivery center and an actual inventory quantity of the at least one factory.

Abstract: The present invention is to provide an anti-trypanosomiasis agent having a high selective toxicity, and high preventing or treating effect against trypanosomiasis, comprising a compound shown by the following general formula (1) as an active ingredient (wherein R1 and R2 each independently represents a hydrogen atom, halogen atom, hydroxyl group, oxygen atom, C1-5 alkyl group, C1-5 alkoxy group, C5-8 aryl group, C5-8 aryloxy group, C2-6 alkoxycarbonyl group or C2-6 alkylaminocarbonyl group, and may be bound to each other; R3, R4, and R5 each independently represents a C1-5 alkyl group or C5-8 aryl group; R6 and R7 each independently represents a hydrogen atom, halogen atom, hydroxyl group, oxygen atom, C1-8 alkyl group, C1-5 alkoxy group, C5-8 aryl group, C5-8 aryloxy group, or C2-6 alkoxycarbonyl group, and may be bound to each other; Y and Z each independently represents an atom group necessary to form a 5- or 6-membered heterocycle; m and n each represent 0 or 1; Q represents a physiologically acceptab

Abstract: It is an object of the present invention to provide: a protein refolding column filler, which is effective for the refolding, namely, the activation of the function, of an inactive protein with an as yet unformed higher order structure produced in Escherichia coli or the like, or a protein whose conformation has been changed due to a certain cause and which has become inactivated; and a column filled with the aforementioned column filler. The present invention provides a protein refolding column filler, which comprises zeolite with BEA structure (Zeolite Beta) that is granulated into a particle state.

Abstract: The present invention is to provide a medicinal composition for preventing or treating parasitic protozoan infections, having a high selective toxicity against parasitic protozoan infection, and a superior preventive or treating effect.

Abstract: A peroxycarboxylic acid represented by the general formula (I): (wherein R1 represents a substituted or unsubstituted C1-C10 alkyl group, or a substituted or unsubstituted C6-C10 aryl group, L represents a substituted or unsubstituted C2-C12 divalent linking group, or R1 and L may combine to form a ring) and a composition comprising said peroxycarboxylic acid are provided. Said peroxycarboxylic acid can sterilize a medical apparatus such as endoscope in a short period of time and has no unpleasant smell.

Abstract: It is an object of the present invention to provide a simple and efficient means capable of evaluating the VH/VL interaction without expressing/purifying VH and VL. The present invention provides a recombinant vector comprising: (i) a nucleotide sequence which can express a hetero-assembly composed of two types of fusion proteins wherein heavy chain variable region (VH) and light chain variable region (VL) of antibody are respectively fused with mutually associable first polypeptide and second polypeptide, by means of secretion, or in a form of a fusion protein tethered to a phage coat protein; and (ii) a restriction enzyme recognition sequence at two sites within, or in a vicinity of, a nucleotide sequence encoding said first polypeptide or second polypeptide.

Abstract: The object of the invention is to provide pharmaceutical composition that can be used as a therapeutic and/or prophylactic agent. Particularly, the pharmaceutical composition of the invention has significant therapeutic effect and survival benefit for the disease caused by parasitic protozoa, and selective toxicity against the causative protozoa. The pharmaceutical composition comprises a compound represented by general formula (1). Particularly, the invention relates to a composition that is an effective therapeutic/prophylactic agent for malaria, leishmania, African sleeping sickness, Chagas disease, toxoplasmosis lymphatic filariasis, babesiosis, and coccidiosis, and a novel compound contained therein.

Abstract: A near infrared fluorescent contrast agent which is excellent in permeability in a living tissue and enables specific imaging of tumor and/or blood vessel, comprising a compound represented by formula (I) or a pharmaceutically acceptable salt thereof, wherein R1, R2, R7, and R8 represent a C1-C10 alkyl group or the like; R3, R4, R5, R6, R9, R10, R11, and R12 represent a hydrogen atom, a C1-C6 alkyl group, an aryl group or the like; X1 and X2 represent a C1-C15 alkyl group or an aryl group and X1 and X2 in total have 0 to 4 carboxyl groups; m1, m2, and m3 represents 0 or 1; L1 to L7 independently represent a methine group; M represents a hydrogen atom, a metal, or a quaternary ammonium salt; and n represents an integer of 1 to 7 necessary for neutralizing charge.

Abstract: The purpose of the present invention is therefore to provide a pharmaceutical composition, especially that for the treatment and/or prevention of parasitic infection by protozoa, which has a high therapeutic effect and selective toxicity or a life-prolongation effect for the parasitic infection by protozoa.

Abstract: A near infrared fluorescent contrast agent which is excellent in permeability in a living tissue and enables specific imaging of tumor and/or blood vessel, comprising a compound represented by formula (I) or a pharmaceutically acceptable salt thereof, wherein R1, R2, R7, and R8 represent a C1-C10 alkyl group or the like; R3, R4, R5, R6, R9, R10, R11, and R12 represent a hydrogen atom, a C1-C6 alkyl group, an aryl group or the like; X1 and X2 represent a C1-C15 alkyl group or an aryl group and X1 and X2 in total have 0 to 4 carboxyl groups; m1, m2, and m3 represents 0 or 1; L1 to L7 independently represent a methine group; M represents a hydrogen atom, a metal, or a quaternary ammonium salt; and n represents an integer of 1 to 7 necessary for neutralizing charge.

Abstract: An object of the present invention is to provides a method for detecting a hydrophobic region of a target substance that is capable of forming a hydrophobic region, such as a protein, which can detect a fluorescent analyte with high sensitivity with the use of a simple detection apparatus. The present invention provides a method for detecting a hydrophobic region of a target substance which comprises steps of allowing a target substance capable of forming a hydrophobic region to come into contact with a chemiluminescent substance, and assaying chemiluminescence.

Abstract: An object to be achieved by the present invention is to provide a method that enables convenient production of a target fusion protein within a short time without constructing any expression vector. The present invention provides a method for producing a fusion protein comprising a first protein and a second protein, which comprises the steps of: introducing a nucleic acid molecule (pre-trans-splicing molecule) or a vector capable of expressing such a nucleic acid molecule into a cell expressing the first protein, wherein the nucleic acid molecule contains a gene sequence encoding the second protein and a sequence which is capable of inducing trans-splicing through binding to pre-mRNA that is generated from a region containing a gene sequence that encodes the first protein; and recovering a fusion protein comprising the first protein and the second protein generated within the cell.

Abstract: The present invention is to provide an anti-trypanosomiasis agent having a high selective toxicity, and high preventing or treating effect against trypanosomiasis, comprising a compound shown by the following general formula (1) as an active ingredient (wherein R1 and R2 each independently represents a hydrogen atom, halogen atom, hydroxyl group, oxygen atom, C1-5 alkyl group, C1-5 alkoxy group, C5-8 aryl group, C5-8 aryloxy group, C2-6 alkoxycarbonyl group or C2-6 alkylaminocarbonyl group, and may be bound to each other; R3, R4, and R5 each independently represents a C1-5 alkyl group or C5-8 aryl group; R6 and R7 each independently represents a hydrogen atom, halogen atom, hydroxyl group, oxygen atom, C1-8 alkyl group, C1-5 alkoxy group, C5-8 aryl group, C5-8 aryloxy group, or C2-6 alkoxycarbonyl group, and may be bound to each other; Y and Z each independently represents an atom group necessary to form a 5- or 6-membered heterocycle; m and n each represent 0 or 1; Q represents a physiologically accepta

Abstract: An object of the present invention is to provide a microorganism which has a high ability of producing docosahexaenoic acid. The present invention provides a Thraustochytrium strain which has an ability of producing docosahexaenoic acid, and use thereof.

Abstract: A peroxycarboxylic acid represented by the general formula (I): (wherein R1 represents a substituted or unsubstituted C1-C10 alkyl group, or a substituted or unsubstituted C6-C10 aryl group, L represents a substituted or unsubstituted C2-C12 divalent linking group, or R1 and L may combine to form a ring) and a composition comprising said peroxycarboxylic acid are provided. Said peroxycarboxylic acid can sterilize a medical apparatus such as endoscope in a short period of time and has no unpleasant smell.

Abstract: An object of the present invention is to provide a biosensor comprising a hydrogel capable of immobilizing a physiologically active substance thereon, which can be produced conveniently by use of a safe material, and a method for producing the same. The present invention provides a method for producing a biosensor, which comprises bringing a polymer containing an activated carboxyl group into contact with a substrate surface coated with an organic layer having an amino group to thereby bind the polymer to the organic layer.